News

APPs discuss insurance barriers, dupilumab as the default COPD biologic, depemokimab adherence advantages, and why pulmonary rehab remains critically underused.

Pulmonologists weigh in on biologic selection, mepolizumab tachyphylaxis, COPD payer barriers, and why asthma outcomes far outpace COPD in real-world practice.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

In this Q&A following EAC 2026, Blumenthal discusses perioperative anaphylaxis risk stratification, hidden OR triggers, and penicillin allergy de-labeling.

Jason Hawkes, MD, highlights issues related to prior authorization as well as raising awareness of chronic urticaria, HS, atopic dermatitis, and other diseases.

Hear Philip Adamson, MD, MSc, discuss his path through heart failure and his work with Abbott and CVRx.

Richard Lafayette, MD, discusses how atacicept's FDA approval advances BAFF/APRIL targeting in IgA nephropathy.

Ann Marie Navar, MD, PhD, highlights enlicitide’s FDA approval for hypercholesterolemia and its potential to fundamentally change therapy.

Monopar initiated a rolling NDA submission for ALXN1840, an investigational therapy for Wilson disease targeting copper dysregulation.

Jason Hawkes, MD, explains how targeted therapies are advancing precision medicine and reshaping personalized care for atopic dermatitis.

Phase 2 data suggest zabopegdutide improved liver fat, stiffness, and fibrosis biomarkers within 12 weeks in adults with MASH.

Most newer nonsteroidal topical options are now approved for children as young as 2 years. Linda Stein Gold, MD, discusses adherence and misconceptions of pediatric AD.

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

Plozasiran cut triglycerides up to 81% and reduced acute pancreatitis events in phase 3 SHASTA-3, SHASTA-4 trials for severe hypertriglyceridemia.

This Q&A highlights the significance of the FDA approval of risankizumab (Skyrizi) for psoriasis and psoriatic arthritis in pediatric patients.

New topical mechanisms introduce more ways to control pediatric AD without the sting, burn, or long-term steroid concerns that limit adherence, Linda Stein Gold, MD, says.

Amy Paller, MD, highlights takeaways from the recent FDA approval of risankizumab-rzaa (Skyrizi) for children with psoriasis and PsA.

Ron Blankstein, MD, discusses a recent study confirming the replicability of CCTA results with AI-CPA in patients with coronary plaque at risk of cardiovascular disease.

Exa-cel requires careful counseling on treatment timelines, chemotherapy conditioning, fertility risks, and the gene therapy journey.

Interim KONFIDENT-S data show breakthrough HAE attacks began to be relieved at a median of 1.2 hours.

FDA expands RYALTRIS® approval to children aged 6 to 11 with seasonal allergic rhinitis, based on phase 3 trial data.

Agios ends tebapivat development in sickle cell disease after phase 2 results show no differentiated benefit.

According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

Stay updated with the latest healthcare breakthroughs, including FDA approvals, phase 3 data, and open-label extension results.

John Sonnenberg, PhD, outlines EMERGE trial criteria, dosing sessions, and endpoints for DT120 (lysergide) ODT 100 µg in major depressive disorder.

Haydar Frangoul, MD, discusses how the expanded indication may allow earlier conversations about curative therapy and intervention before irreversible complications develop.

Ron Blankstein, MD, discusses a secondary analysis of HeartFlow’s DECIDE registry, indicating undetected cardiovascular risk in patients previously labeled safe.